DiaMedica Therapeutics Reports Director Changes and Officer Appointment
Ticker: DMAC · Form: 8-K · Filed: May 23, 2024 · CIK: 1401040
| Field | Detail |
|---|---|
| Company | Diamedica Therapeutics Inc. (DMAC) |
| Form Type | 8-K |
| Filed Date | May 23, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, director-change, officer-appointment
Related Tickers: DMAC
TL;DR
DiaMedica's board is shuffling: new director elected, officer appointed, and a director is out. Check the filings for details.
AI Summary
DiaMedica Therapeutics Inc. filed an 8-K on May 23, 2024, reporting on the departure of a director, the election of a new director, and the appointment of a new officer. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits. The company's principal executive offices are located at 301 Carlson Parkway, Suite 210, Minneapolis, MN 55305.
Why It Matters
Changes in board composition and executive appointments can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance matters and does not appear to disclose significant new financial or operational risks.
Key Players & Entities
- DiaMedica Therapeutics Inc. (company) — Registrant
- May 22, 2024 (date) — Earliest event reported
- May 23, 2024 (date) — Filing date
- 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305 (address) — Principal executive offices
FAQ
Who departed from the board of directors?
The filing indicates the departure of a director, but the specific name is not detailed in the provided text.
Who was elected as a new director?
The filing mentions the election of a new director, but the specific name is not provided in the excerpt.
Was there an appointment of a new officer?
Yes, the filing reports the appointment of a certain officer.
What is the primary business of DiaMedica Therapeutics Inc. according to the filing?
The Standard Industrial Classification code indicates the company is in 'PHARMACEUTICAL PREPARATIONS [2834]'.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 22, 2024.
Filing Stats: 1,129 words · 5 min read · ~4 pages · Grade level 13.2 · Accepted 2024-05-23 16:00:35
Filing Documents
- dmtp20240523_8k.htm (8-K) — 72KB
- ex_678897.htm (EX-10.1) — 214KB
- 0001437749-24-018140.txt ( ) — 456KB
- dmac-20240522.xsd (EX-101.SCH) — 3KB
- dmac-20240522_def.xml (EX-101.DEF) — 11KB
- dmac-20240522_lab.xml (EX-101.LAB) — 14KB
- dmac-20240522_pre.xml (EX-101.PRE) — 11KB
- dmtp20240523_8k_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held a 2024 Annual General Meeting of Shareholders (the "2024 AGM") on May 22, 2024. As of the close of business on March 25, 2024, the record date for the 2024 AGM, there were 37,958,000 voting common shares, no par value, of the Company ("Common Shares") outstanding and entitled to vote at the 2024 AGM. Each Common Share was entitled to one vote. Shareholders holding an aggregate of 25,768,238 Common Shares entitled to vote at the 2024 AGM, representing 67.9% of the outstanding Common Shares as of the record date, and which constituted a quorum thereof, were present in person or represented by proxy at the 2024 AGM. At the 2024 AGM, the Company's shareholders considered five voting proposals, each of which is described in more detail in the Company's 2024 Proxy Statement. The final voting results of each voting proposal brought before a vote of the Company's shareholders at the 2024 AGM are set forth below: Voting Proposal One - Election of Directors. The seven director nominees proposed by the Board were elected to serve as members of the Board until the next annual general meeting of shareholders and until their respective successors are duly elected and qualified by the following final voting results: Votes For Votes Withheld Broker Non-Votes Richard Pilnik 13,544,949 453,382 11,769,907 Michael Giuffre, M.D. 13,654,969 343,362 11,769,907 Tanya Lewis 13,653,388 344,943 11,769,907 James Parsons 13,654,885 343,446 11,769,907 Rick Pauls 13,650,382 347,949 11,769,907 Charles Semba, M.D. 13,660,786 337,545 11,769,907 Richard Kuntz, M.D., M.Sc. 13,654,758 343,573 11,769,907 1 Voting Proposal Two - Appointment of Independent Registered Public Accounting Firm and Authorization to Fix Remuneration. The voting proposal to appoint Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending De
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 10.1 DiaMedica Therapeutics Inc. Amended and Restated Omnibus Incentive Plan (Effective May 22, 2024) 104 The Cover Page from this Current Report on Form 8-K, Formatted in Inline XBRL 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DIAMEDICA THERAPEUTICS INC. By: /s/ Scott Kellen Scott Kellen Chief Financial Officer and Secretary Date: May 23, 2024 4